Abstract

Keywords

Second malignancy after treatment of childhood acute myeloid leukemia

W Leung^1,2,3, RC Ribeiro^2,3, M Hudson^1,2,3, X Tong⁴, DK Srivastava⁴, JE Rubnitz^2,3, JT Sandlund^2,3, BI Razzouk^2,3, WE Evans^3,5 & C-H Pui^2,3

Correspondence to: W Leung, St Jude Children's Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105, USA; Fax: 901 521 9005

To investigate the cumulative incidence of second malignancy and the competing risk of death due to any other cause in patients who were treated for childhood acute myeloid leukemia (AML), we analyzed the outcomes in a cohort of 501 patients who were treated at St Jude Children's Research Hospital between 1970 and 1996. Five patients developed a second cancer (two carcinomas of the parotid gland, one non-Hodgkin's lymphoma, one supratentorial primitive neuroectodermal tumor, one acute lymphoblastic leukemia) as compared with 0.47 expected in the general population (standardized incidence ratio, 10.64; 95% confidence interval, 3.28 to 22.34). A third neoplasm (meningioma) developed in one patient. At 15 years after the diagnosis of AML, the estimated cumulative incidence of second malignancy was 1.34%  0.61%, whereas the cumulative incidence of death due to any other cause was 72.96%  2.14%. We concluded that although a more than 10-fold increased risk of development of cancer was found in survivors of childhood AML as compared to the general population, the risk of this late complication is small when compared to the much larger risk of death because of the primary leukemia or the early complications of its treatment. Future studies should focus on improving treatments for primary AML while preventing second malignancies. Leukemia (2001) 15, 41–45.

^© Macmillan Publishers Ltd 2001